**Biosynthesis and Regulation of the Insulin Receptor**

PHILLIP GORDEN, M.D.,* RICHARD ARAKAKI, M.D.,* ELAINE COLLIER, M.D.,* AND JEAN-LOUIS CARPENTIER, M.D.Δ

*Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; ΔInstitute of Histology and Embryology, University of Geneva School of Medicine, Geneva, Switzerland

Received May 17, 1989

The insulin receptor is an integral glycoprotein of the plasma membrane in most mammalian cells. The gene encodes a 190 kDa proreceptor that undergoes a number of processing steps. The gene is constitutively expressed, but at least one form of regulation has been demonstrated. Glucocorticoids increase the number of insulin receptors on the surface of cultured human lymphocytes, a process which is accompanied by an increase in transcription of the gene. N-linked glycosylation and amide-linked acylation occur as co-translational events. Subsequently, the proreceptor is cleaved into alpha and beta subunits; the subunits then undergo an ester-linked acylation step and N-linked complex glycosylation. In addition, O-linked glycosylation has been recently described in the beta subunit. The mature insulin receptor is inserted into the plasma membrane as an alpha2-beta2 disulfide-linked heterodimer. The receptor can be further regulated on the cell surface by insulin binding and receptor-mediated endocytosis. The receptor concentration on the cell surface then becomes a function of the internalization rate and the receptor recycling rate. Receptor regulation is a relevant feature of many forms of clinical insulin resistance, and recently genetic mutations have been described that determine both the binding properties of the receptor and its translocation and processing properties.

**INTRODUCTION**

The insulin receptor is a cell surface integral membrane protein present in most mammalian cells. The receptor recognizes and binds insulin; the strength of the insulin signal transduced is a function of the concentration of the insulin receptor complex. Thus, the concentration of insulin, of the receptor, or both, may be varied to regulate the magnitude of the insulin signal.

Early studies employing biochemical techniques defined the insulin receptor as a specific protein and defined its steady state binding parameters. More recent studies employing cell biologic techniques have defined mechanisms of regulation, and molecular genetic studies have elucidated the structure and sequence of the receptor, permitting description of specific functional domains. Clinical studies have utilized all of these techniques to describe the relevance of the insulin receptor to a number of diabetic syndromes.

**STRUCTURE OF THE MATURE INSULIN RECEPTOR**

The mature receptor that is inserted into the plasma membrane consists of an alpha subunit that contains the insulin-binding domain and a beta subunit that contains a tyrosine kinase domain (Fig. 1). The insulin receptor is composed of a dimer of two

*Abbreviation: LDL: low-density lipoprotein

Address reprint requests to: Phillip Gorden, M.D., NIDDK—NIH, Building 31, Room 9A52, Bethesda, MD 20892

Copyright © 1989 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.
alpha and two beta subunits linked by disulfide bonds. Insulin binds to the alpha subunit and activates autophosphorylation of the beta subunit. Once phosphorylated, the beta subunit is an activated tyrosine kinase. The details of other forms of phosphorylation of the insulin receptor and subsequently of its substrates are not well understood. [1]. It seems clear, however, that the binding of insulin and receptor autophosphorylation are necessary, if not sufficient, events to trigger insulin action. It is possible that reagents other than insulin, such as insulinomimetic immunoglobulins, may be able to circumvent part of this pathway [2].

**BIOSYNTHESIS OF THE RECEPTOR—THE GENE AND cDNA**

The insulin receptor gene is located on chromosome 19, estimated to be greater than 120 kB, and contains 22 exons [3]. Several groups have identified the 5' flanking region which is noteworthy for the absence of "TATA" and "CAAT" box sequences [3,4,5,6]. There are, however, multiple G-C rich regions that may be possible Sp1 binding sites, consistent with the promoter sequence for many constitutively expressed "housekeeping" genes. By primer extension analysis, many transcriptional initiation sites have been identified in the 5' untranslated region. Transcription is induced by glucocorticoids, but no specific glucocorticoid regulatory sequence has been identified [7,8].

The human insulin receptor cDNA (approximately 5 kB) encodes a single chain proreceptor [9,10], which was previously described by biosynthetic labeling studies [11] (Fig. 2). It is interesting that insulin is also synthesized by way of a single chain precursor [12]. The alpha subunit contains a cysteine-rich region, consistent with the ligand-binding domain. There is also a sequence, with four basic amino acids separating the alpha and beta subunits, which is the site of proteolytic cleavage. The beta subunit has been intensely examined by site-directed mutagenesis to determine necessary functional domains. Of interest are the extracellular, transmembrane, tyrosine kinase, and carboxy terminal regions. Superimposed on this protein backbone are a number of processing events.
BIOSYNTHESIS AND REGULATION OF INSULIN RECEPTOR

FIG. 2. Schematic representation of the human insulin receptor cDNA. The region of the cDNA designated ArgLysArgArg represents the cleavage site between the α- and β-subunits. The Lys 1018 of the β-subunit is the adenosine triphosphate binding site. The region designated Tyr 1146, 1150, and 1151 represents the biologically significant substrates for receptor phosphorylation. Tyr 960, 1316, and 1322 represent phosphorylation sites of uncertain significance.

For the most part, the insulin receptor gene is transcribed in a constitutive fashion, and the concentration of mRNA is directly proportional to the number of receptors on the cell surface [13]. Aside from developmental regulation, and regulation based on cell transformation, the only known positive regulators of insulin receptor gene expression are glucocorticoids [7,8]. In a time- and dose-related fashion, glucocorti-
coids increase the number of insulin receptors on the surface of cultured human lymphocytes. This process is related to the synthetic pathway, inasmuch as the receptor turnover rate is not affected. Receptor mRNA levels are proportionally increased, and this increase is a direct transcriptional effect (Fig. 3). While insulin itself will increase proreceptor synthesis to some extent, this increase is not accompanied by an increase in gene transcription [7].

**BIOSYNTHESIS—RECEPTOR TRANSLATION**

The translation of the insulin receptor message presumably occurs by the same route as other integral membrane proteins, i.e., on membrane-bound ribosomes (Fig. 4). The message encodes a 190 kDa pror receptor protein which undergoes two recognized co-translational events: (a) N-linked glycosylation of the high mannose type and (b) an amide-linked acylation step. There are 18 potential glycosylation sites on the pror receptor, with 14 on the alpha subunit and four on the extracellular domain of the beta subunit. It is noted that there are 15 potential glycosylation sites on the alpha subunit [9,10], but one of these is composed of asn-pro-ser, which is very unlikely to be glycosylated [14]. As with other proteins, a Glc$_3$Man$_9$GlcNac$_2$ oligosaccharide is transferred to an asparagine of the protein via a dolichol phosphate intermediate. This oligosaccharide chain is processed to a complex type of chain by removal of the three glucoses and several mannoses prior to addition of other monosaccharides and sialic acid. If removal of the glucoses is inhibited, the receptor concentration on the cell surface is reduced, suggesting that processing to complex chains is necessary for correct targeting of the receptor to the cell surface [15,16]. Further processing of the high mannose chains to complex chains occurs in the Golgi.

The insulin receptor also contains covalently linked fatty acids. In biosynthetic labeling studies, radiolabeled myristate and palmitate are found attached to the insulin receptor. One of these fatty acids appears to be attached very early, in an amide linkage, as inhibition of protein synthesis prevents its occurrence [17].

As soon as the protein chain is synthesized, possibly as a co-translational event, interchain disulfide dimerization occurs (Fig. 5). Thus, the newly synthesized pror receptor is a disulfide-linked dimer which has undergone high mannose glycosylation and amide-linked acylation. The newly synthesized pror receptor binds insulin but with reduced affinity. The tyrosine kinase activity of the pror receptor is reduced in proportion to the reduced binding affinity (Fig. 6). Thus, the pror receptor, like
proinsulin, is fully active but with diminished affinity as compared to the mature peptide.

**PROCESSING OF THE PRORECEPTOR**

Further processing of the proreceptor presumably occurs in the Golgi apparatus. Cleavage of the proreceptor to produce the pre-alpha and pre-beta subunits occurs very early, but probably in the Golgi. The mature alpha subunit has an apparent molecular weight of 135 kDa and the mature beta subunit, one of 95 kDa. The insulin receptor contains both high mannose and complex type of N-linked oligosaccharides since the mature receptor contains endoglycosidase-sensitive carbohydrates [18]. The difference in molecular weight of the alpha and beta subunits from that predicted by the amino acid sequence is largely attributed to N-linked glycosylation.

Two additional processing steps less well characterized probably occur in the Golgi. In addition to the amide-linked fatty acid, there is ester linkage of fatty acids to the insulin receptor. Both the alpha and beta subunits contain covalently bound fatty acids [17]. The part that these fatty acids play in receptor function and processing is unknown at the present time.

Recently, another post-translational modification of the insulin receptor has been described, O-linked glycosylation [19]. N-glycanase, an enzyme that specifically removes N-linked oligosaccharides, removes all of the carbohydrate moieties from the proreceptor and the alpha subunit, whereas, in the beta subunit, in addition to
FIG. 6. Insulin dose-response autophosphorylation of immunoprecipitated mature insulin receptor and proreceptor. Mature receptor and precursor from IM-9 cells were isolated by sequential lectin chromatography and immunoprecipitation with site-specific anti-receptor antibody. Left panel: Autophosphorylation response to increasing concentrations of insulin in the β-subunit (95 kDa) isolated by wheat germ agglutinin chromatography followed by SDS-polyacrylamide gel electrophoresis and autoradiography. Right panel: The proreceptor (190 kDa) isolated by lentil-wheat germ chromatography followed by SDS-polyacrylamide gel electrophoresis and autoradiography. Note the attenuation in phosphorylation in the proreceptor as compared to the mature β-subunit.

N-glycanase, O-glycanase, an enzyme that specifically removes O-linked oligosaccharides, is required to remove all of the carbohydrate. The O-linked carbohydrate is apparently limited to a single tryptic peptide fragment which also contains N-linked carbohydrate. The significance of this newly described O-linked glycosylation to the function or processing of the insulin receptor is presently unknown.

THE FULLY PROCESSED RECEPTOR

Following the processing events described, the mature receptor is transferred from the Golgi to the plasma membrane. The nature of this transfer process is unknown, but it would appear the receptor is inserted into the membrane in a random fashion; however, once inserted into the membrane, the receptor is freely mobile in the plane of the plasma membrane. This finding is based on morphometric studies that have shown that 125I-insulin binds initially in a preferential fashion to the microvillus surface of the membrane and, with time at 37°C, redistributes to the non-villus surface [20]. Other evidence for mobility comes from fluorescent microscopy and from electron microscopic autoradiographic studies that have shown that the insulin receptor complex redistributes to the Golgi pole of the cell when the temperature of initial binding is increased to 37°C. There is no evidence for an extensive intracellular pool of fully processed receptors that can be immediately recruited to the plasma membrane, as reported for the glucose transporter when the cell is stimulated by insulin.
The $t/2$ for receptor turnover in cultured human lymphocytes is approximately six to eight hours [21]; this rate is augmented by insulin binding. This "down-regulation" or ligand-induced receptor regulation was the first evidence for a process that appears to be general for most polypeptide hormones [22]. The mechanism of this down-regulation appears to be receptor-mediated endocytosis of the insulin receptor complex [20].

**RECEPTOR-MEDIATED ENDOCYTOSIS OF THE INSULIN RECEPTOR COMPLEX**

When $^{125}$I-insulin, under physiologic conditions, binds to cell surface receptors on cultured or freshly isolated cells, the hormone receptor complex is internalized. Subsequently, a series of intracellular events ensues that can dissociate the hormone from its receptor (Fig. 7).

A number of experimental observations suggest that internalization is the major mechanism by which cell surface insulin receptors are "down-regulated." In cultured human lymphocytes, receptor gene transcription is not affected by down-regulating conditions [7]. In fact, there is a small increase in proreceptor translation under these circumstances [23]. In other cells, there is an effect to inhibit gene transcription analogous to the effect of internalized cholesterol in the down-regulation of the low-density lipoprotein (LDL) receptor [24].

The structures involved in endocytosis appear to be relatively nonspecific and similar for many other polypeptide hormones, growth factors, and other unrelated ligands. Labeled insulin is initially localized in coated pits on the cell surface which invaginates, fuses, and then fissions to form coated vesicles. These vesicles rapidly lose their clathrin coat and progressively become larger non-coated structures called endosomes. The acidification of endosomes promotes dissociation of the ligand receptor.
complex, permitting the ligand and receptor to be processed independently [20]. Furthermore, the beta subunit of the receptor with its tyrosine kinase domain oriented toward the cytoplasmic surface could potentially interact with other proteins or structures as an activated tyrosine kinase [25].

The receptor appears to be recycled predominantly from this endosomal compartment based on kinetic analysis, but morphologic data have demonstrated that the receptor can be recycled from other vesicular structures such as lysosomes. Whether there is some interaction of the recycling vesicles with those vesicles involved in the transfer of newly synthesized receptors from the Golgi to the cell surface is at present unknown. Furthermore, it is not clear how specificity is determined, inasmuch as many different polypeptides appear to be recycled in the same or similar vesicles [20]. It is known that certain types of receptors, such as the LDL receptor, recycle continuously, whereas internalization and recycling of the insulin receptor predominantly requires ligand binding. Thus, down-regulation of the receptor is primarily determined by the rate of receptor endocytosis and the rate of receptor recycling.

MECHANISMS REGULATING RECEPTOR-MEDIATED ENDOCYTOSIS

The internalization of the insulin receptor occurs predominantly by way of coated pits [20]. Whether this is an exclusive mechanism, however, is uncertain, inasmuch as exclusive coated-pit internalization has been shown, to date, only for the LDL receptor. Two mechanisms have received recent attention. The first is that insulin receptors with a mutation at the adenosine triphosphate binding site that prevents autophosphorylation are not internalized [26,27], which suggests a possible role for autophosphorylation in the endocytic event. On the other hand, many ligand receptors such as the growth hormone receptor [28] and the LDL receptor are not phosphorylated. Thus, phosphorylation cannot be a general mechanism regulating endocytosis. The other interesting question is whether the process is driven by a specific amino acid sequence in the intracytoplasmic region of the receptor. In this regard, a consensus sequence among several types of receptors, including the LDL receptor and the class I antigen receptor, has been suggested [29].

RELEVANCE OF THE INSULIN RECEPTOR TO CLINICAL DISEASE

Insulin resistance is a dominant and central feature in obesity, typical type II diabetes, and in several syndromes of extreme alternation of insulin action. Thus, the insulin receptor has a pivotal role in the study of insulin resistance. In obesity and type II diabetes, the receptor is "down-regulated." This ligand-induced regulation, presumably mediated by internalization, decreases the concentration of insulin receptors on the cell surface and, therefore, is a potential factor in clinical insulin resistance; this condition may occur in addition to any other post-receptor defect.

In both type I and type II diabetes, receptor-mediated endocytosis of the insulin receptor is impaired, suggesting that there may be a mechanism for maintaining insulin receptors on the cell surface under circumstances where insulin action is reduced [30,31,32]. Thus "down-regulation" is a feature of most hyperinsulinemic states, whether diabetes is present or not. The impaired internalization appears to be primarily a feature of the hyperglycemic diabetic state and can be reversed with insulin therapy.

Furthermore, several genetic defects have now been elucidated that are associated with extreme forms of insulin resistance (Table 1). In one of these disorders, a specific
mutation in the alpha subunit impairs the translocation of newly synthesized receptors to the plasma membrane, which results in a low concentration of insulin receptors on the plasma membrane and insulin resistance. The second processing defect involves a mutation at the cleavage site which inhibits proreceptor processing to the mature subunits; this defect results in insertion of a low-affinity receptor into the plasma membrane and insulin resistance.

ACKNOWLEDGEMENT

This manuscript is dedicated to Dr. Philip K. Bondy for his extraordinary service to scientific investigation, scientific journalism, and teaching. Each has had a great influence on present-day medicine.

REFERENCES

1. Kahn CR, White MF: The insulin receptor and the molecular mechanism of insulin action. J Clin Invest 82:1151–1156, 1988
2. Forsayeth JR, Caro JF, Sinha MK, Maddux BA, Goldfine ID: Monoclonal antibodies to the human insulin receptor that activate glucose transport but not insulin receptor kinase activity. Proc Natl Acad Sci USA 84:3448–3451, 1987
3. Seino S, Seino M, Nishi S, Bell GI: Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 86:114–118, 1989
4. Araki E, Shimada F, Uzawa H, Mori M, Ebina Y: Characterization of the promoter region of the human insulin receptor gene: Evidence for promoter activity. J Biol Chem 262:16186–16191, 1987
5. Mamula PW, Wong K-Y, Maddux BA, McDonald AR, Goldfine ID: Sequence and analysis of promoter region of human insulin-receptor gene. Diabetes 37:1241–1246, 1988
6. McKeon C, Moncada V, Barr V, Accili D, Frapier C, Taylor SI: Transcscriptional regulation of the human insulin receptor (Abstract). Clinical Research 37:572A, 1989
7. Rouiller DG, McKeon C, Taylor SI, Gordon P: Hormonal regulation of insulin receptor gene expression: Hydrocortisone and insulin act by different mechanisms. J Biol Chem 263:13185–13190, 1988
8. McDonald AR, Goldfine ID: Glucocorticoid regulation in insulin receptor gene transcription in IM-9 cultured lymphocytes. J Clin Invest 81:499–504, 1988
9. Ebina Y, Ellis L, Jarngin K, Edery M, Graf L, Clauer E, Ou J, Masiarz F, Kan YW, Goldfine ID, Roth RA, Rutter WJ: The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling. Cell 40:747–758, 1985
10. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM Dull TJ, Gray A, Coussens L, Liao Y-C, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313:756–761, 1985
11. Hedo JA, Gorden P: Biosynthesis of the insulin receptor. Horm Metabol Res 17:487–490, 1985
12. Steiner DF, Oyer PE: The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. Proc Natl Acad Sci USA 57:473–480, 1967
13. Ojamaa K, Hedo JA, Roberts CT, Moncada VY, Gorden P, Ullrich A, Taylor SI: Defects in human insulin receptor gene expression. Mol Endo 2:242–247, 1988
14. Kobata A: The carbohydrates of glycoproteins. In Biology of Carbohydrates. Vol 2. Edited by VGinsburg, PW Robbins. New York, Wiley Publishers, 1984, pp 87–161
15. Arakaki RF, Hedo JA, Collier E, Gorden P: Effects of castanospermine and 1-deoxynojirimycin on insulin receptor biogenesis. J Biol Chem 262:11886–11892, 1987
16. Duronio V, Jacobs S, Romero PA, Herscovics A: Effects of inhibitors of N-linked oligosaccharide processing on the biosynthesis and function of insulin and insulin-like growth factor-I receptors. J Biol Chem 263:5436–5445, 1988
17. Hedo JA, Collier E, Watkinson A: Myristyl and palmitoyl acylation of the insulin receptor. J Biol Chem 262:954–957, 1987
18. Hedo JA, Kasuga M, Van Obberghen E, Roth J, Kahn CR: Direct demonstration of glycosylation of insulin receptor subunits by biosynthetic labeling: Evidence for heterogeneity. Proc Natl Acad Sci USA 78:4791–4795, 1981
19. Collier E, Gorden P: The insulin receptor contains O-linked oligosaccharides (Abstract). Diabetes 38(2):178A, 1989
20. Gorden P, Carpentier J-L, Orci L: Insulin action at the cellular level: Anatomical considerations. In Diabetes/Metabolism Reviews. Edited by RA De Fronzo. New York, John Wiley & Sons, 1985, pp 99–117
21. McElduff A, Hedo JA, Taylor SI, Roth J, Henden P: Insulin receptor degradation is accelerated in cultured lymphocytes from patients with genetic syndromes of extreme insulin resistance. J Clin Invest 74:1366–1374, 1984
22. Gavin JR, Roth J, Neville DM, DeMeyts P, Buell DN: Insulin dependent regulation of insulin receptor concentrations. A direct demonstration in cell culture. Proc Natl Acad Sci USA 71:84–88, 1974
23. Rouiller D, Henden P: Homologous down-regulation of the insulin receptor is associated with increased receptor biosynthesis in cultured human lymphocytes (IM-9 line). Proc Natl Acad Sci USA 84:126–130, 1987
24. Okabayashi Y, Maddux BA, McDonald AR, Logsdon CD, Williams JA, Goldfine ID: Mechanisms of insulin-induced insulin-receptor downregulation: Decrease of receptor biosynthesis and mRNA levels. Diabetes 38:182–187, 1989
25. Carpentier J-L, White MF, Orci L, Kahn CR: Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells. J Cell Biol 105:2751–2762, 1987
26. Russell DS, Gherzi R, Johnson EL, Chou C-K, Rosen OM: The protein-tyrosine kinase activity of the insulin receptor is necessary for insulin-mediated receptor down-regulation. J Biol Chem 262:11833–11840, 1987
27. Hari J, Roth RA: Defective internalization of insulin and its receptor in cells expressing mutated insulin receptors lacking kinase activity. J Biol Chem 262:15341–15344, 1987
28. Asakawa K, Grunberger G, McElduff A, Gorden P: Polypeptide hormone receptor phosphorylation: Is there a role in receptor-mediated endocytosis of human growth hormone? Endocrinol 117:631–637, 1985
29. Vega MA, Strominger JL: Constitutive endocytosis of HLA class I antigens requires a specific portion of the intracytoplasmic tail that shares structural features with other endocytosed molecules. Proc Natl Acad Sci USA 86:2688–2692, 1989
30. Carpentier J-L, Robert A, Grunberger G, Van Obberghen E, Freychet P, Orci L, Gorden P: Receptor-mediated endocytosis of polypeptide hormones is a regulated process: Inhibition of [125I]iodoinsulin internalization in hypoinsulinemic diabetes of rat and man. J Clin Endocrinol Metab 63:151–155, 1986
31. Trischitta V, Gullo D, Squarrito S, Pezzino V, Goldfine ID, Vigneri R: Insulin internalization into monocytes is decreased in patients with type II diabetes mellitus. J Clin Endocrinol Metab 62:522–528, 1986
32. Geiger D, Carpentier J-L, Gorden P, Orci L: Down regulation of insulin receptors is related to insulin internalization. Submitted for publication
33. Accili D, Frapier C, Mostaf L, McKeeon C, Elbein SC, Permuth MA, Ramos E, Lander E, Ullrich A, Taylor SI: A mutation in the insulin receptor gene that impairs transport of the receptor to the plasma membrane and causes insulin resistant diabetes. EMBD J 8:2509–2517, 1989
34. Yoshimasa Y, Seino S, Whittaker J, Kakehi T, Kosaki A, Kuzuya H, Imura H, Bell GI, Steiner DF: Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science 240:784–787, 1988
35. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI: Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 240:787–790, 1988
36. Odawara M, Kadowaki T, Yamamoto R, Shibasaki Y, Tobe K, Accili D, Bevins C, Mikami Y, Matsuura N, Akanuma Y, Takaku F, Taylor SI, Kasuga M: A mutation in the tyrosine kinase domain of the insulin receptor of an insulin-resistant patient. Science 245:66–68, 1989
37. Moller DE, Flier JS: Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance). N Engl J Med 319:1526–1529, 1988